Pier 88 Investment Partners LLC Grows Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Pier 88 Investment Partners LLC increased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 20.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 161,730 shares of the company’s stock after acquiring an additional 27,820 shares during the quarter. Pier 88 Investment Partners LLC’s holdings in Recursion Pharmaceuticals were worth $1,093,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Decker Retirement Planning Inc. purchased a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth about $26,000. Private Trust Co. NA purchased a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at about $27,000. GAMMA Investing LLC lifted its holdings in shares of Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after buying an additional 4,948 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after buying an additional 1,353 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in Recursion Pharmaceuticals by 220.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company’s stock valued at $66,000 after acquiring an additional 6,758 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. KeyCorp lowered their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Leerink Partners dropped their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Friday, February 28th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.25.

Recursion Pharmaceuticals Stock Down 2.7 %

RXRX opened at $5.81 on Monday. The company has a market cap of $2.34 billion, a PE ratio of -3.80 and a beta of 0.85. Recursion Pharmaceuticals, Inc. has a twelve month low of $5.59 and a twelve month high of $12.36. The company has a 50-day moving average price of $7.44 and a 200 day moving average price of $7.01. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. During the same period in the previous year, the company earned ($0.42) EPS. Recursion Pharmaceuticals’s revenue was down 57.8% compared to the same quarter last year. Sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.